JP2005501083A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005501083A5 JP2005501083A5 JP2003518654A JP2003518654A JP2005501083A5 JP 2005501083 A5 JP2005501083 A5 JP 2005501083A5 JP 2003518654 A JP2003518654 A JP 2003518654A JP 2003518654 A JP2003518654 A JP 2003518654A JP 2005501083 A5 JP2005501083 A5 JP 2005501083A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- group
- cancer
- carbonic anhydrase
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 18
- 201000010099 disease Diseases 0.000 claims 17
- 150000001875 compounds Chemical class 0.000 claims 16
- 230000001613 neoplastic effect Effects 0.000 claims 10
- 229940002612 prodrug Drugs 0.000 claims 10
- 239000000651 prodrug Substances 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 9
- 229940122072 Carbonic anhydrase inhibitor Drugs 0.000 claims 7
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 claims 7
- 102000003846 Carbonic anhydrases Human genes 0.000 claims 6
- 108090000209 Carbonic anhydrases Proteins 0.000 claims 6
- 229940093444 Cyclooxygenase 2 inhibitor Drugs 0.000 claims 6
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 6
- 239000002246 antineoplastic agent Substances 0.000 claims 5
- -1 cyano, carboxyl Chemical group 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 229940122204 Cyclooxygenase inhibitor Drugs 0.000 claims 3
- 206010058202 Cystoid macular oedema Diseases 0.000 claims 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 3
- 208000001344 Macular Edema Diseases 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 206010038389 Renal cancer Diseases 0.000 claims 3
- 201000007455 central nervous system cancer Diseases 0.000 claims 3
- 208000029742 colonic neoplasm Diseases 0.000 claims 3
- 201000010206 cystoid macular edema Diseases 0.000 claims 3
- 125000001475 halogen functional group Chemical group 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 201000010982 kidney cancer Diseases 0.000 claims 3
- 208000032839 leukemia Diseases 0.000 claims 3
- 201000005202 lung cancer Diseases 0.000 claims 3
- 208000020816 lung neoplasm Diseases 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 claims 3
- 125000000565 sulfonamide group Chemical group 0.000 claims 3
- 201000002862 Angle-Closure Glaucoma Diseases 0.000 claims 2
- 206010030113 Oedema Diseases 0.000 claims 2
- 206010030348 Open-Angle Glaucoma Diseases 0.000 claims 2
- 206010061323 Optic neuropathy Diseases 0.000 claims 2
- 201000001326 acute closed-angle glaucoma Diseases 0.000 claims 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 2
- 125000004414 alkyl thio group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000030533 eye disease Diseases 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 208000020911 optic nerve disease Diseases 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- JADGCGSQDUSAED-UHFFFAOYSA-N 5-fluoro-1-(3-oxo-1h-2-benzofuran-1-yl)pyrimidine-2,4-dione Chemical group O=C1NC(=O)C(F)=CN1C1C2=CC=CC=C2C(=O)O1 JADGCGSQDUSAED-UHFFFAOYSA-N 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000001441 Familial Periodic Paralyses Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 206010027423 Metabolic alkalosis Diseases 0.000 claims 1
- 208000034388 Mountain sickness acute Diseases 0.000 claims 1
- 208000018315 acute mountain sickness Diseases 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 claims 1
- 125000000278 alkyl amino alkyl group Chemical group 0.000 claims 1
- 125000004689 alkyl amino carbonyl alkyl group Chemical group 0.000 claims 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims 1
- 125000004471 alkyl aminosulfonyl group Chemical group 0.000 claims 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 1
- 125000006350 alkyl thio alkyl group Chemical group 0.000 claims 1
- 125000004691 alkyl thio carbonyl group Chemical group 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 125000004103 aminoalkyl group Chemical group 0.000 claims 1
- 125000005097 aminocarbonylalkyl group Chemical group 0.000 claims 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 239000003101 antineoplastic hormone agonist and antagonist Substances 0.000 claims 1
- 125000005099 aryl alkyl carbonyl group Chemical group 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 125000004659 aryl alkyl thio group Chemical group 0.000 claims 1
- 125000001769 aryl amino group Chemical group 0.000 claims 1
- 125000005129 aryl carbonyl group Chemical group 0.000 claims 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 claims 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 1
- 125000005110 aryl thio group Chemical group 0.000 claims 1
- 125000005164 aryl thioalkyl group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 125000004181 carboxyalkyl group Chemical group 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000004966 cyanoalkyl group Chemical group 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 206010016208 familial periodic paralysis Diseases 0.000 claims 1
- 208000035474 group of disease Diseases 0.000 claims 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 1
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 229940124452 immunizing agent Drugs 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31156101P | 2001-08-10 | 2001-08-10 | |
| PCT/US2002/025447 WO2003013655A2 (en) | 2001-08-10 | 2002-08-09 | Carbonic anhydrase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005501083A JP2005501083A (ja) | 2005-01-13 |
| JP2005501083A5 true JP2005501083A5 (US06815460-20041109-C00023.png) | 2005-12-22 |
Family
ID=23207450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003518654A Withdrawn JP2005501083A (ja) | 2001-08-10 | 2002-08-09 | 炭酸脱水酵素阻害剤 |
Country Status (7)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030100594A1 (en) * | 2001-08-10 | 2003-05-29 | Pharmacia Corporation | Carbonic anhydrase inhibitor |
| CA2526578C (en) * | 2003-05-22 | 2012-01-24 | Pharmacia Italia S.P.A. | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors |
| LT5504B (lt) * | 2006-08-02 | 2008-06-25 | Biotechnologijos Institutas | Benzimidazo[1,2-c][1,2,3]tiadiazolo sulfonamidai - karboanhidrazių slopikliai ir tarpiniai junginiai jiems gauti |
| EP2491014A1 (en) * | 2009-10-21 | 2012-08-29 | Bayer Pharma Aktiengesellschaft | Substituted halophenoxybenzamide derivatives |
| JP6795525B2 (ja) * | 2015-07-01 | 2020-12-02 | シグナルケム・ライフサイエンシーズ・コーポレイションＳｉｇｎａｌｃｈｅｍ Ｌｉｆｅｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ | 炭酸脱水酵素阻害剤としてのアリールスルホンアミド化合物およびその治療的使用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2139281C1 (ru) * | 1993-11-30 | 1999-10-10 | Джи Ди Сирл энд Компани | Пиразолилзамещенный бензолсульфонамид или его фармацевтически приемлемая соль, фармацевтическая композиция, способ лечения от воспаления или связанного с воспалением заболевания |
| JP3181190B2 (ja) * | 1994-12-20 | 2001-07-03 | 日本たばこ産業株式会社 | オキサゾール誘導体 |
| US5944021A (en) * | 1995-06-07 | 1999-08-31 | Rodriguez; Victorio C. | Therapeutic use of a carbonic anhydrase enzyme inhibitor for the treatment of brain edema |
| EP0892791B1 (en) * | 1996-04-12 | 2003-03-05 | G.D. Searle & Co. | N-[[4-(5-METHYL-3-PHENYLISOXAZOL-4-YL]PHENYL]SULFONYLPROPYLAMIDE and its SODIUMSALT AS PRODRUGS OF COX-2 INHIBITORS |
| US6323226B1 (en) * | 1999-10-19 | 2001-11-27 | Texas Heart Institute | Treatment of heart disease with cox-2 inhibitors |
-
2002
- 2002-08-09 EP EP02768491A patent/EP1414522A2/en not_active Withdrawn
- 2002-08-09 AU AU2002331050A patent/AU2002331050A1/en not_active Abandoned
- 2002-08-09 BR BR0211836-0A patent/BR0211836A/pt not_active IP Right Cessation
- 2002-08-09 CA CA002456939A patent/CA2456939A1/en not_active Abandoned
- 2002-08-09 MX MXPA04001268A patent/MXPA04001268A/es unknown
- 2002-08-09 WO PCT/US2002/025447 patent/WO2003013655A2/en not_active Application Discontinuation
- 2002-08-09 JP JP2003518654A patent/JP2005501083A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ509755A (en) | Method of using benzenesulphoamides that are cyclooxygenase-2-inhibitors in the treatment and prevention of neoplasia | |
| SI9720035B (sl) | Substituirani benzensulfonamidni derivati kot predzdravila COX-2 inhibitorjev | |
| KR100779285B1 (ko) | 미세 자가-유화성 약학 조성물의 제조 방법 | |
| KR100765614B1 (ko) | 유방염 및 이질환 치료용 분산성 제약 조성물 | |
| ATE296114T1 (de) | Zubereitungen, enthaltend einen cyclooxygenase-2- inhibitor und einen leukotrien-b4-rezeptor- antagonisten | |
| RU2325189C2 (ru) | Способ и фармацевтическая композиция для доставки противовоспалительного средства | |
| JP2004526765A5 (US06815460-20041109-C00023.png) | ||
| ES2252448T3 (es) | Composicion parenteral reconstituible que contiene un inhibidor de la cox-2. | |
| JP2005539023A5 (US06815460-20041109-C00023.png) | ||
| KR20040012761A (ko) | 안정화된 경구 약학적 조성물 | |
| US20030105141A1 (en) | Finely self-emulsifiable pharmaceutical composition | |
| AU2002305175A1 (en) | Orally deliverable pharmaceutical composition comprising a drug of low water solubility (COX-2 inhibitor), a solvent, a fatty acid and an organic amine | |
| JP2005501850A5 (US06815460-20041109-C00023.png) | ||
| JP2005501083A5 (US06815460-20041109-C00023.png) | ||
| US20060111345A1 (en) | Pharmaceutical compositions comprising a selective COX-2 inhibitor and a diuretic | |
| US20040033938A1 (en) | Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis | |
| EP1526847A2 (en) | Pharmaceutical dosage form comprising a sulfite compound | |
| US20040105884A1 (en) | Pharmaceutical dosage form comprising a sulfite compound | |
| US20040105883A1 (en) | Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage | |
| JP2007500692A (ja) | 乳房炎及び耳障害を治療するための分散性医薬組成物 | |
| KR20210090367A (ko) | 항암제에 의해 유도되는 이질통의 예방 또는 치료용 조성물 및 이를 이용한 치료방법 | |
| RU2024111332A (ru) | Ресметиром для уменьшения объема печени | |
| Stein et al. | THU0400 Inhibition of IL-6 signalling: A novel therapeutic approach for familial mediterranean fever | |
| JP2001521889A5 (US06815460-20041109-C00023.png) | ||
| ZA200307575B (en) | Orally deliverable pharmaceutical composition comprising a drug of low water solubility (cox-2inhibitor), a solvent, a fatty acid and an organic amine. |
